Skip to main content
Figure 2 | Proteome Science

Figure 2

From: A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line

Figure 2

Panel of Lucena cross-resistance to IM treatment. (A) K562 and Lucena cell lines were treated with a range of IM doses for 24 h. Cell viability was measured by trypan blue exclusion assay. Apoptotic cells (B) and cell cycle (C) were measured by flow cytometry after 1 μM of IM treatment in both cell lines. (D) ABCG2, OCT1 and BCR-ABL mRNA expression levels in K562 and Lucena cell lines were quantified by RT-qPCR. Expression values were normalized to β-actin expression. Values represent the means of three independent determinations ± s.d. (*p < 0.05; **p < 0.01; ***p < 0.001)

Back to article page

Proteome Science

ISSN: 1477-5956